Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 258 results found since Jan 2013.
Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition
Publication date: Available online 11 December 2020Source: Chinese Chemical LettersAuthor(s): Jing Gao, Hanwu Zhang, Fengqi Zhou, Bo Hou, Meiwan Chen, Zhigang Xie, Haijun Yu
Source: Chinese Chemical Letters - December 12, 2020 Category: Chemistry Source Type: research
Photo ‐Enhanced CRISPR/Cas9 System Enables Robust PD‐L1 Gene Disruption in Cancer Cells and Cancer Stem‐Like Cells for Efficient Cancer Immunotherapy
This study provides an alternative strategy to block the PD‐1/PD‐L1 pathway for efficacious immune checkpoint therapy.
Source: Small - December 2, 2020 Category: Nanotechnology Authors: Liang Zhao,
Yingli Luo,
Qiaoyi Huang,
Ziyang Cao,
Xianzhu Yang Tags: Full Paper Source Type: research
A Web-Based Platform on Coronavirus Disease-19 to Maintain Predicted Diagnostic, Drug, and Vaccine Candidates.
In this study, state-of-the-art techniques have been used for predicting the potential candidates for diagnostics and therapeutics.
PMID: 33136473 [PubMed - as supplied by publisher]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - November 3, 2020 Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer
Conclusions: Taken together, these results provide evidence to suggest that therapeutic approaches targeting USP7, in combination with immunotherapy, should be considered for lung cancer treatment.
Source: Theranostics - October 3, 2020 Category: Molecular Biology Authors: Xiaomeng Dai, Lisen Lu, Suke Deng, Jingshu Meng, Chao Wan, Jing Huang, Yajie Sun, Yan Hu, Bian Wu, Gang Wu, Jonathan F. Lovell, Honglin Jin, Kunyu Yang Tags: Research Paper Source Type: research
Cancers, Vol. 12, Pages 2857: The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC
on Strandmann
Drugs targeting epigenetic mechanisms such as histone deacetylase inhibitors (HDACi) suppress tumor growth. HDACi also induce the expression of ligands for the cytotoxicity receptor NKG2D rendering tumors more susceptible to natural killer (NK) cell-dependent killing. The major acetylases responsible for the expression of NKG2D ligands (NKG2D-L) are CBP and p300. The role of the oncogene and transcriptional repressor SKI, an essential part of an HDAC-recruiting co-repressor complex, which competes with CBP/p300 for binding to SMAD3 in TGFβ signaling, is unknown. Here we show that the siRNA-me...
Source: Cancers - October 2, 2020 Category: Cancer & Oncology Authors: Viviane Ponath Miriam Frech Mathis Bittermann Reem Al Khayer Andreas Neubauer Cornelia Brendel Elke Pogge von Strandmann Tags: Article Source Type: research
Cancers, Vol. 12, Pages 2603: Inhibition of Caspases Improves Non-Viral T Cell Receptor Editing
In this study, we attempt to solve the problem by screening small molecule drugs with an immortalized human T cell line, Jurkat clone E6-1, for inhibition of apoptosis. The study identifies a few caspase inhibitors that could be used to simultaneously enhance the cell viability and the efficiency of plasmid DNA electrotransfer. Additionally, we show that the enhancement could be achieved through knockdown of caspase 3 expression in siRNA treated cells, suggesting that the cell death in electrotransfer experiments was caused mainly by caspase 3-dependent apoptosis. Finally, we investigated if the caspase inhibitors could im...
Source: Cancers - September 10, 2020 Category: Cancer & Oncology Authors: Chunxi Wang Chun-Chi Chang Liangli Wang Fan Yuan Tags: Article Source Type: research
MicroRNA ‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer
ConclusionsmiR200b can regulate PD ‐L1 expression in lung cancer cells, and miR200b expression in clinical specimens negatively correlated with PD‐L1 expression. Thus, miR200b may be a useful surrogate biomarker for PD‐L1 expression in lung cancer patients.Key pointsSignificant findings of the study
High PD ‐L1 expression was linked to low miR200b expression, whereas low PD‐L1 expression was linked to high miR200b expression in human lung cancer patients. Thus, miR200b overexpression or silencing can control PD‐L1 expression in cancer cells.What this study adds
We demonstrated the potential of miR200b as a surr...
Source: Thoracic Cancer - September 6, 2020 Category: Cancer & Oncology Authors: Seigo Katakura,
Nobuaki Kobayashi,
Hisashi Hashimoto,
Chisato Kamimaki,
Katsushi Tanaka,
Sousuke Kubo,
Kentaro Nakashima,
Shuhei Teranishi,
Saki Manabe,
Keisuke Watanabe,
Nobuyuki Horita,
Yu Hara,
Masaki Yamamoto,
Makoto Kudo,
Hongmei Piao, Tags: ORIGINAL ARTICLE Source Type: research
Blockade of CD73 delays glioblastoma growth by modulating the immune environment
This study indicates that CD73 knockdown using a nanotechnological approach to perform nasal delivery of siRNA-CD73 to CNS can potentially regulate the glioblastoma immune microenvironment and delay tumor growth by inducing apoptosis.
Source: Cancer Immunology, Immunotherapy - August 13, 2020 Category: Cancer & Oncology Source Type: research
Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis
Conclusions: Our results demonstrated that TREM1 could be used as a novel immunotherapy target for glioma patients.
Source: Frontiers in Immunology - July 15, 2020 Category: Allergy & Immunology Source Type: research
RNA Nanotechnology-Mediated Cancer Immunotherapy
RNA molecules (e.g., siRNA, microRNA, and mRNA) have shown tremendous potential for immunomodulation and cancer immunotherapy. They can activate both innate and adaptive immune system responses by silencing or upregulating immune-relevant genes. In addition, mRNA-based vaccines have recently been actively pursued and tested in cancer patients, as a form of treatment. Meanwhile, various nanomaterials have been developed to enhance RNA delivery to the tumor and immune cells. In this review article, we summarize recent advances in the development of RNA-based therapeutics and their applications in cancer immunotherapy. We als...
Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Yao-Xin Lin, Yi Wang, Sara Blake, Mian Yu, Lin Mei, Hao Wang, Jinjun Shi Tags: Review Source Type: research
Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via modulation of a novel CMKLR1-mediated signaling cascade.
CONCLUSIONS: Collectively, our data show a novel link between chemerin, PTEN and PD-L1 in human tumor cells, that may have a role in improving T cell-mediated immunotherapies.
PMID: 32605911 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 29, 2020 Category: Cancer & Oncology Authors: Rennier KR, Shin WJ, Krug E, Virdi GS, Pachynski RK Tags: Clin Cancer Res Source Type: research
Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle
ConclusionOverall, results revealed that the tumors treated with siPDIN restored the immunity of CTLs by potentially inhibiting the immune checkpoint interactions, suppressed the mTOR signaling pathway and exhibited an enhanced anticancer efficacy in melanoma.
Source: Pharmaceutical Research - May 30, 2020 Category: Drugs & Pharmacology Source Type: research
CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model
The interaction of lymphoma cells with their microenvironment has an important role in disease pathogenesis and is being actively pursued therapeutically using immunomodulatory drugs, including immune checkpoint inhibitors. Diffuse large B-cell lymphoma (DLBCL) is an aggressive high-grade disease that remains incurable in ~40% of patients treated with R-CHOP immunochemotherapy. The FOXP1 transcription factor is abundantly expressed in such high-risk DLBCL and we recently identified its regulation of immune response signatures, in particular, its suppression of the cell surface expression of major histocompatibility class I...
Source: Frontiers in Oncology - April 2, 2020 Category: Cancer & Oncology Source Type: research
